Itovebi access in Saudi Arabia: the SFDA named-patient pathway
How Saudi Arabia patients legally obtain Itovebi (inavolisib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Itovebi in Saudi Arabia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Itovebi (inavolisib) is PI3K-alpha selective inhibitor and degrader approved by the US FDA in October 2024 for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with palbociclib and fulvestrant, in patients with disease recurrence on or within 12 months of completing adjuvant endocrine therapy. The drug is manufactured by Genentech/Roche. Saudi Arabia patients use the Saudi Food and Drug Authority named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates supply through a US-licensed pharmaceutical wholesale partner, builds the documentation packet your physician needs to file, and orchestrates the logistics into Saudi Arabia with a single point of contact carrying the case end-to-end.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Itovebi reaches patients in Saudi Arabia
Itovebi (inavolisib, an oral PI3K-alpha-isoform-specific inhibitor with degradation activity against mutant PI3K-alpha, FDA-approved October 2024 in combination with palbociclib and fulvestrant for endocrine-resistant PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy; marketed by Genentech, a member of the Roche Group) is not currently visible on the SFDA registered-drug list at sfda.gov.sa/en/drugs-list as of 2026-05-31. Saudi residents access Itovebi through Personal Importation of Medicines (SFDA Clearance Permit for Personal Use) under SFDA Document Drug-6567E at sfda.gov.sa Drug-6567E PDF, or via the SFDA Special Access Programme (Pathway B) for institutional access. The Itovebi-specific clinical justification must document: confirmed PIK3CA mutation status (the FDA label requires a companion-diagnostic-detected PIK3CA mutation by FoundationOne CDx tissue or liquid biopsy), HR-positive HER2-negative breast cancer with recurrence on or after adjuvant endocrine therapy, the intended triple combination with palbociclib and fulvestrant, and the prescribing oncologist's licensure. Baseline fasting glucose and HbA1c per the FDA label (hyperglycaemia is a class effect of PI3K-alpha inhibitors) are referenced in the supporting medical report. The report must be dated within 6 months of submission.
Where Itovebi is dispensed in Saudi Arabia
Itovebi is an oral combination-regimen breast-oncology therapy; the dispensing setting is breast-oncology-experienced medical oncology with capacity for PIK3CA companion-diagnostic testing and ongoing fasting-glucose and HbA1c surveillance. Saudi tertiary oncology nodes include King Faisal Specialist Hospital and Research Centre (KFSHRC) Department of Medical Oncology and Comprehensive Cancer Center in Riyadh and Jeddah at kfshrc.edu.sa, which runs structured breast-oncology services and has institutional capacity for PIK3CA companion-diagnostic testing; King Fahad Medical City (KFMC) Comprehensive Cancer Center Breast Oncology in Riyadh at kfmc.med.sa; King Abdulaziz Medical City (KAMC) Princess Noorah Oncology Center Breast Oncology in Riyadh and Jeddah; Prince Sultan Military Medical City Oncology in Riyadh; King Fahad Specialist Hospital Dammam Oncology; and King Abdulaziz University Hospital Department of Oncology in Jeddah. KFSHRC is the most-likely dispensing node nationally for Itovebi given the institutional capacity for the FoundationOne CDx companion diagnostic and the structured breast-oncology service. The clinical workflow co-manages the PI3K-alpha-inhibitor-class hyperglycaemia risk with the same institution's endocrinology service.
What Itovebi costs in Saudi Arabia
Medicine price: quote on request. You get a written quote for your case before you commit. Do not estimate.
Funding and access barriers for Itovebi in Saudi Arabia
HR-positive HER2-negative breast cancer is the most common breast-cancer subtype in Saudi tertiary practice; PIK3CA mutations occur in approximately 35 to 40% of HR-positive metastatic breast cancers, placing the Itovebi-eligible population at meaningful scale. The historical management of endocrine-resistant disease in this population spans CDK4/6 inhibitors plus endocrine therapy, alpelisib plus fulvestrant in PIK3CA-mutated cases, and other combinations; Itovebi is the second PI3K-alpha-class inhibitor (after alpelisib) but with a more selective profile. Public-sector funding: Saudi nationals receive specialty oncology care at MOH-affiliated centres without direct charge; NUPCO procurement covers registered breast-oncology drugs, but Itovebi is not currently on the NUPCO list. Institutional access via SFDA Special Access Programme is procedurally available with clinical committee approval based on documented PIK3CA mutation status and endocrine-therapy-resistant disease. The Council of Health Insurance Essential Benefits Package adjudicates the floor for cooperative-insurance coverage; major Saudi insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Al Rajhi Takaful, Walaa Cooperative, SAICO) extend Itovebi coverage on higher-tier policies with prior authorisation and documented step-therapy. Roche Saudi Arabia operates a patient-support programme for selected oncology biologics; case-by-case Itovebi access support is at early-launch stage as of 2026-05-31. Out-of-pocket exposure is most material for expatriates outside the MOH-funded channel.
Recent regulatory and access news for Itovebi
FDA approved Itovebi (inavolisib) on 10 October 2024 based on the INAVO120 phase 3 trial demonstrating significant PFS improvement in the triplet combination versus palbociclib plus fulvestrant in PIK3CA-mutated HR+ HER2- endocrine-resistant metastatic breast cancer. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) issued a positive opinion for inavolisib in early 2025 with subsequent European Commission approval; the EMA EPAR is at ema.europa.eu/medicines/Itovebi. Roche has prioritised global launch including the Middle East. The SFDA News feed at sfda.gov.sa/en/news does not document an Itovebi-specific bulletin over the last 12 months as of 2026-05-31; SFDA submission timing has not been publicly disclosed by Roche Saudi Arabia.
Where Reserve Meds fits in Itovebi cases
Reserve Meds is a US-based digital health company. We do not replace your Saudi specialist, we do not replace the SFDA, and we do not replace your dispensing pharmacy. For Itovebi specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate logistics into Saudi Arabia, and give you one point of contact through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your Saudi physician has prescribed Itovebi and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.